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ABSTRACT 
Evolution has allowed bacteria to develop sophisticated methods of survival. One 
of these methods is biofilm production.  Biofilms can be best described as complex 
bacterial communities embedded in a self-producing slime. Once bacteria form these 
biofilm communities, they become very difficult to treat with antibiotics. Along with 
biofilm production, another rising concern is antibiotic resistance. Bacterial resistance 
to many of our current antibiotics is sharply increasing, thereby creating a critical need 
to develop novel antimicrobial drugs. 
The most successful strategy for the discovery of new antibacterial agents has 
been the study of molecules from nature.  Most of our current clinical antibiotics 
derive from metabolites produced by bacteria.  Antimicrobial compounds of plant 
origin also have enormous therapeutic potential. Previous studies have demonstrated 
that certain plant metabolites have potent inhibitory effects on the growth of 
pathogenic bacteria. Not only might metabolites from plants help mitigate infectious 
diseases, but they may also lack adverse side effects often associated with existing 
antimicrobial agents, including hypersensitivity, allergic reaction, and 
immunosuppression. Therefore, future efforts to discover new antimicrobial drugs 
should also include the evaluation of new natural products from both microbes and 
plants. 
In this thesis, Chapter 1 describes an investigation to classify and quantify biofilm 
production in unique clinical strains of methicillin-resistant Staphylococcus aureus 
(MRSA). Staphylococcus aureus bacteria are responsible for causing a wide range of 
diseases and many are capable of biofilm production.  To date, the largest focus of 
  
biofilm research has been on S. epidermidis and Pseudomonas aeruginosa. Few 
investigators have addressed the basic and central question: “What percentage of our 
clinical S. aureus bacteria produce biofilms and from what patient source are they 
most likely identified?”  Two hundred and nineteen (n = 219) clinical methicillin-
resistant S. aureus (MRSA) isolates obtained from patients at the Veterans Affairs 
Medical Center (VAMC) in Providence, Rhode Island were evaluated. I evaluated 
biofilm formation using a modified microtiter-plate assay, and used a statistical 
approach to quantifying biofilm production.  The results indicate that biofilm 
production is most frequently encountered in clinical MRSA from catheter sources. 
The surface area of these catheters may provide the ideal conditions for biofilm 
growth, especially in urine. Interestingly, a lesser incidence of biofilm production was 
observed by MRSA isolates obtained in the nares. 
Chapter 2 describes a phytochemical investigation of plant metabolites from 
Hypericum species that inhibit bacterial growth as well as biofilm production in Gram-
positive bacteria. For this study, seven acylphloroglucinol metabolites were obtained 
from Dr. Geneive Henry at Susquehanna University.  I tested each compound in 
assays that measure both bacterial growth and biofilm production. The results showed 
that not only do some of these metabolites inhibit bacterial growth, but they also 
inhibit biofilm growth at sub-MIC concentrations.  Important findings from this 
investigation included new structure-activity relationships demonstrating the 
importance of certain functional groups to the antibacterial nature of these metabolites. 
These results suggest that Hypericum spp. deserve further attention as a source of new 
antimicrobial agents. 
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CHAPTER 1 
 
The following manuscript has been formatted for submission to the journal 
Diagnostic Microbiology and Infectious Disease. 
 
Biofilm-Producing Strains of Clinical Methicillin-Resistant Staphylococcus 
aureus are Most Frequently Encountered from Catheters  
 
Simon A. Sarkisian
1,2
 and Kerry L. LaPlante
1,2*
 
 
University of Rhode Island, Department of Pharmacy Practice
1
  
Infectious Diseases Research Laboratory, Providence Veterans Affairs Medical 
Center
2
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ABSTRACT 
We classified and quantified biofilm production in clinical methicillin-resistant 
Staphylococcus aureus (MRSA) isolates obtained from patient blood, nares, tissue, 
urine and catheter sources.  Overall, 30.6% of the MRSA isolates were biofilm 
producers. Cultures obtained from catheter sources were significantly more likely to 
produce biofilm (52.3%, n=44, P=0.0005) compared to the other sources. 
Interestingly, cultures obtained from patient nares were significantly less likely to 
produce biofilm (18.6%, n=59, P=0.0198).   
 
INTRODUCTION 
 
Methicillin-resistant Staphylococcus aureus (MRSA) produce an extracellular 
mucoid substance often referred to as a biofilm (Arciola, Campoccia, & Montanaro, 
2002). The main component is polysaccharidic in nature and consists of 
glycosaminoglycans (Arciola, Baldassarri, & Montanaro, 2001). Biofilm formation is 
linked with the pathogenicity of most bacteria, including the Staphylococcus species, 
allowing them to better persist in the normally hostile environment of tissue and 
blood. Additionally, the physical barrier imposed by biofilms impedes antibiotic 
effectiveness and host defenses (Ceri, et al., 1999; Donlan, 2000; Oie, Huang, Kamiya, 
Konishi, & Nakazawa, 1996). 
 It is well known that Staphylococcus epidermidis produce biofilm, and it is 
estimated that greater than 60% of these isolates are capable of this production 
(Arciola, et al., 2001; Arciola, et al., 2002; Christensen, Simpson, Bisno, & Beachey, 
1982; Cramton, Gerke, & Gotz, 2001; Cramton, Ulrich, Gotz, & Doring, 2001; de 
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Araujo, et al., 2006; Donlan, et al., 2001). However, much less is known about biofilm 
producing abilities in MRSA, particularly with clinical isolates. Therefore, it was the 
intent of this project to 1) measure biofilm formation by clinical strains of MRSA 
obtained from patients at the Veteran Affairs Medical Center (VAMC) in Providence, 
Rhode Island, 2) assess the frequency of biofilm production in clinical MRSA isolates, 
and 3) classify the relationship of biofilm producing MRSA to the source of patient 
obtainment (blood, nares, tissue, urine, and catheters). 
 
MATERIALS AND METHODS 
Biofilm production in methicillin-resistant Staphylococcus aureus (MRSA) 
was measured and classified in 219 unique clinical MRSA isolates obtained from 
patients at the Providence VAMC.  The strains were collected from patient blood, 
nares, tissue, urine, and catheters from January 2004 to January 2009.  Known biofilm 
producing S. aureus (ATCC 35556) and S. epidermidis (RP62A; ATCC 35984) were 
used as positive controls. A stable biofilm-negative mutant, M7, from the wild-type S. 
epidermidis RP62A served as the non-biofilm control. 
 Biofilm formation was evaluated and quantified using a modified microtiter-
plate assay (Christensen, et al., 1985; Stepanovic, Vukovic, Dakic, Savic, & Svabic-
Vlahovic, 2000) and growth conditions were optimized for biofilm production in 
staphylococci (Cramton, Gerke, et al., 2001; Cramton, Ulrich, et al., 2001; LaPlante & 
Woodmansee, 2009).  Based on optical density measurements (OD610), bacterial films 
were classified into the following categories: biofilm production or no biofilm 
production using the method established by Stepanovic et al. (Stepanovic, et al., 
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2000). Statistical Analysis Software (SAS) (Version 9.1) was used for all analyses, 
and a P-value of ≤ 0.05 was considered statistically significant. 
 
RESULTS 
Assays conducted with known biofilm producing strains S. aureus (ATCC 
35556) and S. epidermidis (RP62A; ATCC 35984) resulted in average OD610 readings 
of 1.87±0.61 and 1.76±0.64, respectively.  The non-biofilm producing staphylococci 
produced with an average OD610 reading of 0.26±0.09.   
Overall, 30.6% (67/219) of the MRSA isolates were determined to be biofilm 
producers.  Biofilm production was most common among isolates obtained from 
catheter sources (52.3%, P=0.0005).  Of interest, isolates obtained from the nares were 
significantly less likely to produce biofilm (18.6% formed biofilm; P=0.0198).  
 
Table 1: Biofilm Production Based on Isolate Source 
Source 
(n = 219) 
Biofilm Production 
%, (n) 
No Biofilm Production 
%, (n) 
Catheter  
(n = 44) 
52.3%, (23) 47.7%, (21) 
Urine  
(n = 13) 
30.8%, (4) 69.2%, (9) 
Tissue   
(n = 56) 
30.4%, (17) 69.6%, (39) 
Blood   
(n = 47) 
25.5%, (12) 74.5%, (35) 
Nares   
(n = 59) 
18.6%, (11) 81.4%, (48) 
Total: 30.6%, (67) 69.4%, (152) 
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Figure 1: Biofilm Production Based on Isolate Source (Presented as % Biofilm 
Production) 
69.4 69.4 69.4 69.4 69.4
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Total No Biofilm Produced Isolate Biofilm Produced
p-value*: 
0.0198
p-value*: 
NS
p-value*: 
0.0005
* P value is source versus others, i.e. blood versus non-blood.  
 
DISCUSSION 
Staphylococcus aureus are the leading cause of bacterial infections in the 
United States and cause a wide range of diseases from simple skin infections to 
potentially fatal systemic diseases (Suzuki, Swoboda, Campbell, Walker, & Gilmore, 
2010). Many staphylococcal infections, such as endocarditis and osteomyelitis, are 
caused by biofilm producing strains (Donlan, 2000; Donlan, et al., 2001).  In total, it is 
estimated that biofilms are associated with 65% of all hospital acquired infections in 
the United States and account for health care costs exceeding one billion dollars 
annually (Licking, 1999; Martone, Jarvis, Culver, & Haley, 1992). 
p-value*: 
NS 
p-value*: 
NS 
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 To date, the largest focus of biofilm research has been on Staphylococcus 
epidermidis and Pseudomonas aeruginosa (Fey & Olson, 2010; Jensen, Givskov, 
Bjarnsholt, & Moser, 2010). Fewer studies have examined biofilm formation by S. 
aureus.  Thus, knowledge is currently lacking regarding the percentage of clinical 
MRSA that produce biofilms and from what patient sources they are most likely 
encountered. 
Interestingly, MRSA isolates obtained from patients’ nares were significantly 
less likely to be biofilm formers compared to isolates obtained from the other patient 
sources. We are not aware of this finding previously discussed in the literature.  
Another study found that 60% of methicillin-resistant Staphylococcus epidermidis 
(MRSE) isolates obtained from the nares were able to produce biofilm (de Araujo, et 
al., 2006).  
 In our facility, we found that cultures taken from catheter samples produced 
significantly more biofilm than other sources.  These results are similar to  those found 
by a Japanese study, which concluded that the biofilm-forming capacities of MRSA 
isolates from catheter-related cases were significantly greater than those from catheter-
unrelated cases (Ando, Monden, Mitsuhata, Kariyama, & Kumon, 2004). Their studies 
suggest that MRSA colonization and infection of the urinary tract may be promoted by 
hla, hlb, and fnbA gene products (Ando, et al., 2004).  However, many genes can be 
responsible for biofilm growth in S. aureus (Houston, Rowe, Pozzi, Waters, & O'Gara, 
2011; Kaito, et al., 2011). Our clinical MRSA isolates were not tested for biofilm-
producing genes because of this lack of standardization.   
 16 
 
 Urinary surfaces provide attractive sites for bacterial colonization as well as 
antibacterial resistance due to the gentle flow of warm nutritious urine (Stickler, 
2008). The capacity of a microorganism to establish and form a biofilm on a given 
surface depends of the nature of the surface in question (Donlan & Costerton, 2002). 
When a device such as a urinary catheter is exposed to bodily fluids such as urine, 
various components adsorb onto the surface and form a conditioning film. This film 
essentially covers the surface and becomes the bona fide interface where microbial 
interaction takes place. In the case of biofilm formation the steps are bacterial 
attachment, microcolony formation and build up of biofilm. It follows that the nature 
of the material constituting the catheter determines the composition of the 
conditioning film, which in turn influences which microorganisms can attach 
(Ferrieres, Hancock, & Klemm, 2007). 
In conclusion, based on the data from our study, a correlation may exist 
between biofilm production and catheters as the source. This may be explained by the 
high likelihood of S. aureus cultures that are taken from urinary and central venous 
catheters.  Of equal interest is the lesser incidence of biofilm formation by MRSA 
isolates derived from patient nares.  
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ABSTRACT 
Biofilm embedded bacterial pathogens such as Staphylococcus spp., 
Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii are difficult 
to eradicate and are major sources of bacterial infections. New drugs are needed to 
combat these pathogens.  Hypericum is a plant genus that contains species known to 
have antimicrobial properties. However, the specific metabolites responsible for the 
antimicrobial properties are not entirely known, nor have most compounds been tested 
as inhibitors of biofilm development. The investigation presented here tested seven 
secondary metabolites isolated from the species Hypericum densiflorum, Hypericum 
ellipticum, Hypericum prolificum, and Hypericum punctatum as inhibitors of bacterial 
growth and biofilm production. Assays were conducted against Staphylococcus 
epidermidis, Staphylococcus aureus, clinical methicillin-resistant Staphylococcus 
aureus (MRSA), Pseudomonas aeruginosa, Escherichia coli, and Acinetobacter 
baumannii. Five of the seven metabolites demonstrated growth inhibition against the 
Gram-positive bacteria with minimum inhibitory concentrations (MIC) ranging from 
1.95 µg/mL to 7.81 µg/mL. Four of the metabolites inhibited biofilm production by 
certain Gram-positive strains at sub-MIC concentrations. 
 
INTRODUCTION 
Bacterial resistance to many of our current antibiotics is sharply increasing, 
thereby creating a critical need to develop novel antimicrobial drugs (Spellberg et al., 
2004). Antimicrobials of plant origin have enormous therapeutic potential.  Not only 
could they help mitigate infectious diseases, but they may also lack adverse side 
 23 
 
effects often associated with existing antimicrobial agents, including hypersensitivity, 
allergic reaction, and immunosuppression (Iwu et al., 1999; Mukherjee et al., 2002). 
Previous investigations have demonstrated the effectiveness of plant metabolites from 
traditional herbs against Gram-positive and Gram-negative microorganisms 
(Dall'agnol et al., 2005; Gibbons, 2004; Mukherjee et al., 2002).  In particular, studies 
involving members of the genus Hypericum have suggested that their metabolites 
possess promising antimicrobial properties.  
The plants of the Clusiaceae (Guttiferae) family consist of more than 1000 
species of which Hypericum is the most widely studied genus (Dall'agnol et al., 2005). 
These plants are commonly found as herbs, shrubs or small trees and are distributed 
primarily in the temperate regions of the world.  Hypericum has been used in folk 
medicine dating back more than 2400 years, thereby suggesting the therapeutic 
potential of many species.  Records indicate that Cherokee, Iroquois, and Montagnais 
American Indian tribes used Hypericum perforatum, also known as St. John’s wort, as 
a febrifuge/cough medicine (Saddiqe et al., 2010).  
There is a growing interest in Hypericum metabolites because of their wide 
range of biological activities.  Phytochemical investigations on Hypericum 
perforatum, for instance, have led to the isolation of active antimicrobial compounds, 
which include naphthodianthrones and phloroglucinols (Saddiqe et al., 2010).  Owing 
to these findings, we were inspired to expand the search for new antibacterial 
metabolites to include other Hypericum species.  Here we report the biological 
evaluation of seven phloroglucinol derivatives from H. densiflorum, H. ellipticum, H. 
prolificum and H. punctatum for their antibacterial properties.  The compounds were 
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tested for inhibition of bacterial growth and biofilm formation against a panel of 
clinically relevant pathogens.  The panel was comprised of Staphylococcus 
epidermidis, Staphylococcus aureus, clinical methicillin-resistant S. aureus (MRSA), 
Pseudomonas aeruginosa, Escherichia coli, and Acinetobacter baumannii. Five of the 
compounds demonstrated potent antimicrobial effects against the Gram-positive 
pathogens.  Additionally, four of the metabolites attenuated biofilm formation at 
concentrations below the minimum inhibitory concentration.   
 
Figure 1: Structures of Hypericum metabolites.  
 
 
 
MATERIALS AND METHODS 
Chemicals and Instrumentation. NMR spectra were recorded on a JEOL ECP 400 
MHz spectrometer (
1
H, 400 MHz; 
13
C, 100 MHz) using CDCl3, (CD3)2CO and 
DMSO-d6 as solvents and TMS as internal standard.  Gradient HMQC and HMBC 
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data were obtained using standard pulse programs.  MS analyses were carried out on a 
Q-Star Elite (Applied Biosystems MDS) mass spectrometer equipped with a Turbo 
Ionspray source (University of Rhode Island).   HRMS data were acquired using 
electrospray ionization on an Agilent G6520A Q-TOF high resolution mass 
spectrometer (CUNY, Hunter College). Preparative HPLC was performed using a 
Waters Delta 600 system equipped with a Waters 2487 dual wavelength absorbance 
detector.  Column chromatography (CC) was performed using Fisher Scientific silica 
gel (230-400 mesh), and analytical TLC was performed using Sigma-Aldrich polyester 
backed plates precoated with silica gel UV254.   All solvents were HPLC grade and 
were obtained from Fisher Scientific and Aldrich Chemical Co.    
Plant material.  All plant samples were collected and identified by Joseph A. Isaac of 
Civil and Environmental Consultants, Pittsburgh, Pennsylvania (PA), USA. The aerial 
portions (leaves and stems) were collected and voucher specimens have been 
deposited at the Carnegie Museum Herbarium in Pittsburgh, PA.  Hypericum 
densiflorum Pursh. was collected in Westmoreland County, PA, in June 2005 (voucher 
#18640) and September 2007 (voucher # 19442). Hypericum ellipticum (voucher 
#20714) was collected in Clearfield County, PA, in August 2009.  Hypericum 
prolificum L. (voucher #18641) was collected in Lawrence County, PA, in June 2005 
and H. punctatum Lam., spotted St. John’s wort, (voucher #18944) was collected in 
Lawrence County, PA, in September 2005.  
Extraction and isolation procedures.  Compounds 3, 4, and 5 were isolated from 
hexanes and acetone extracts of H. densiflorum as previously described (Henry et al., 
2009). Compound 7 was isolated from the hexanes extract of H. prolificum as 
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previously reported (Henry et al., 2006). Aerial parts of H. ellipticum were oven dried 
at 38 C and ground to a fine powder using a coffee grinder. The plant material (459 g) 
was extracted sequentially at room temperature using hexanes (3  1.0 L), acetone (3 
 1.0 L) and methanol (3  1.0 L). The solvents were allowed to percolate for 24 h 
each time. The combined extracts for each solvent were concentrated in vacuo. The 
acetone extract (14.6 g) was fractionated using silica gel CC to afford fractions A1-
A11, eluted with a solvent gradient of acetone-hexanes (5:95 to 100:0, v/v).  Fraction 
A3 (509 mg), eluted with acetone-hexanes (1:3, v/v), was further fractionated with 
ethyl acetate-hexanes (1:4 to 1:3, v/v) to afford a brown solid (145 mg), which was 
purified by semi-preparative HPLC (Atlantis dC18 column, 5 m, 19  150 mm, 
methanol-water (4:1, v/v), isocratic elution, flow rate 10 mL/min) to afford compound 
6 (28.0 mg). The structure of compound 6 was established based on NMR 
spectroscopic and mass spectrometric data (Manning et al., 2011). 
 The aerial parts of H. punctatum were dried and ground to a fine powder using 
a coffee grinder. The powdered plant material (255 g) was extracted with acetone (3 × 
1.1 L) followed by methanol (3 × 1.0 L) at room temperature. The solvents were 
allowed to percolate for one night each time. The acetone and methanol extracts were 
concentrated in vacuo. The acetone extract (15.5 g) was subjected to silica gel CC, 
eluting with an acetone-hexanes stepwise solvent gradient (5:95 to 100:0, v/v) to 
afford nine fractions (A1-A9). Fraction A5 (520 mg), eluted with acetone-hexanes 
(1:4, v/v), was chromatographed further by silica gel CC using ethyl acetate-hexanes 
(1:9 to 1:4, v/v) to afford sub-fractions B1-B6. Subfraction B3 (294.2 mg) was 
purified by semi-preparative HPLC on an Atlantis dC18 column (19 × 150 mm, 
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methanol:water (85:15, v/v), isocratic elution, flow 10 mL/min), to afford compound 1 
(40.2 mg) and compound 2 (55.1 mg) as yellow solids. The NMR spectroscopic data 
of 1 and 2 are consistent with those reported in the literature (Rios and Delgado, 
1992).  
Microorganisms and culture conditions. Staphylococcus epidermidis (RP62A; 
ATCC 35984), S. aureus (ATCC 35556), clinical methicillin-resistant S. aureus, P. 
aeruginosa (ATCC 27853), E. coli (ATCC 25922), and A. baumannii (ATCC 17978) 
were obtained from the Veterans Affairs Medical Center (VAMC) in Providence, 
Rhode Island and maintained in tryptic soy broth (Difco, Becton Dickinson) at -80 ºC. 
All strains were incubated on tryptic soy agar (Difco, Becton Dickinson) at 37 ºC for 
24 h. The clinical MRSA isolate is a biofilm-producing strain that was obtained in 
2004 from the blood of an infected patient at the VAMC in Providence, RI. 
Antimicrobial activity. Bacterial cells (10
5
 CFU/mL) were inoculated into Mueller-
Hinton broth (Difco, Becton Dickinson) at 200 µL/well in 96-well microtiter plates. 
The minimum inhibitory concentration (MIC) of each pure metabolite was determined 
following methods recommended by the Clinical and Laboratory Standards Institute 
(CLSI) (2006a; 2006b). Briefly, two-fold serial dilutions of each compound were 
added to wells containing bacterial cells. After 24 h of incubation at 37 ºC, MICs were 
determined by visually inspecting each well for bacterial growth. The minimum 
bactericidal concentration (MBC), defined as the minimum concentration required to 
kill 99.9% of a bacteria inoculums, was determined by re-inoculating 20 µL of each 
culture medium from the microtiter plate wells onto tryptic soy agar plates. After 24 h 
of incubation at 37 ºC, MBCs were determined by visually inspecting the agar plates 
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for bacterial growth. All MIC and MBC measurements were performed at least in 
duplicate. 
Biofilm Inhibition. Hypericum metabolites that demonstrated growth inhibitory 
properties against staphylococci were tested for their ability to prevent biofilm 
formation by planktonic S. aureus and S. epidermidis. Biofilm production was 
quantified using a microtiter plate assay (Stepanovic et al., 2000). After overnight 
growth on tryptic soy agar (Difco, Becton Dickinson), stationary cultures of the 
biofilm-producing reference strains S. aureus (ATCC 35556), S. epidermidis (RP62A; 
ATCC 35984), and non-biofilm producing staphylococci were evaluated.  A stable 
biofilm-negative mutant, M7, from the wild-type S. epidermidis RP62A served as the 
non-biofilm control. After 24 h of incubation at 37 °C, tryptic soy broth (Bacto, 
Becton Dickinson) and planktonic bacteria were removed by gently washing with 
sterile normal saline.  The minimum biofilm inhibitory concentration (MBIC), which 
is the lowest concentration of an antimicrobial agent that results in no detectable 
biofilm growth, was quantified by staining the bacteria with 2% crystal violet and 
measuring optical density at 570 nm (Synergy 2, Bio-Tek Instruments, Inc, Winooski, 
VT). Wells containing sterile medium served as blanks for all absorbance readings and 
the non-biofilm isolate was used as a negative control. All tests were conducted in 
quadruplicate and the results were averaged. 
 
RESULTS AND DISCUSSION 
 Each of the seven metabolites was first tested for growth inhibitory properties 
against the panel of pathogens. Compounds 1-5 demonstrated potent growth inhibition 
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of the Gram-positive bacteria (Table 1), with MIC and MBC values ranging from 1.95 
µg/mL to 7.81 µg/mL. The MBC values closely mirrored the MIC values, suggesting 
a bactericidal mechanism of action. A comparison of MIC values for metabolites 3-5 
shows that the acyl group modulates potency only minimally. The benzoyl derivative 
5, isolated from H. densiflorum, is the most potent congener in this series, registering a 
MIC of 1.95 µg/mL against biofilm-producing S. aureus.  
Additional structure-activity relationships are apparent from the variable 
activities of the metabolites. Attachment of the geranyl group to either C3 of the 
phloroglucinol ring (1 and 2) or the C2-oxygen (3-5) had little effect on the 
antibacterial properties of the Hypericum metabolites.  However, a previous study 
reported that similar acylphloroglucinol compounds from Hypericum beanii lacking 
the geranyl chain were 2-4 fold less active against S. aureus (Shiu and Gibbons, 2006), 
highlighting the importance of this structural feature. Compounds 6 and 7 did not 
produce any measurable activity against the Gram-positive bacteria. Introduction of a 
methyl group and a second prenyl group (compound 6), leading to loss of aromaticity 
in the phloroglucinol ring, resulted in loss of antibacterial activity. Elaboration of the 
terpene moiety to include an additional two isoprene units (compound 7) also 
abolished the antibacterial effects. The additional cyclization would limit 
conformational flexibility of the terpene unit. The additional prenyl groups also 
increase the lipophilicity, which would likely limit aqueous solubility and therefore 
decrease intracellular concentrations (Appendino et al., 2008).  Winkelmann et al. 
reported modest anti-staphylococcal activity (32 µg/mL) for a related
  
Table 1: MIC/MBC and MBIC activities of Hypericum metabolites.  All values are reported in μg/mL. 
 Biofilm Producing 
 S. epidermidis  
(RP62A; ATCC 35984) 
Non-Biofilm Producing 
S. epidermidis 
(M7) 
Biofilm Producing 
S. aureus  
(ATCC 35556)  
 
Clinical MRSA  
(L32) 
Compound MIC MBC MBIC MIC MBC MBIC MIC MBC MBIC MIC MBC MBIC 
1 7.81 7.81 1.95 7.81 7.81 3.91 7.81 7.81 3.91 3.91 3.91 3.91 
2 3.91 3.91 1.95 3.91 3.91 1.95 7.81 7.81 1.95 3.91 3.91 7.81 
3 7.81 7.81 1.95 7.81 7.81 3.91 3.91 3.91 3.91 7.81 7.81 3.91 
4 3.91 7.81 3.91 3.91 7.81 3.91 3.91 3.91 7.81 7.81 7.81 7.81 
5 3.91 7.81 3.91 3.91 3.91 3.91 1.95 3.91 3.91 3.91 3.91 3.91 
6 >125 >125 125 >125 >125 125 >125 >125 125 >125 >125 125 
7 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 >125 
 
1 represents 3-geranyl-1-(2-methylpropanoyl)phloroglucinol, 2 represents 3-geranyl-1-(2-methylbutanoyl)phloroglucinol, 3 represents 
2-geranyloxy-1-(2-methylpropanoyl)phloroglucinol, 4 represents 2-geranyloxy-1-(2-methylbutanoyl)phloroglucinol, 5 represents 2-
geranyloxy-4,6-dihydroxybenzophenone, 6 represents elliptophenone A, 7 represents prolificin A
3
0
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acylphloroglucinol lacking one of the additional isoprene units of 7, further 
demonstrating the detrimental effects of the cyclization and/or increased lipophilicity 
(Winkelmann et al., 2003). 
Although five of the Hypericum compounds displayed growth inhibitory 
effects against the Staphylococcus test strains, all were inactive against the Gram-
negative bacteria (E. coli, P. aeruginosa, A. baumanii) at the highest test concentration 
of 125 µg/mL. Structural differences between Gram-positive and Gram-negative 
bacterial cell walls may account for the variable activities. Gram-negative bacteria 
possess an outer lipopolysaccharide membrane surrounding the cell wall whereas 
Gram-positive bacteria do not. The lack of an outer lipopolysaccharide membrane in 
the Gram-positive bacteria may allow increased permeability of Hypericum 
metabolites into cells (Tian et al., 2009). These results are in agreement with previous 
studies of Hypericum extracts that have shown weak to no activity against E. coli 
(Bussmann et al., 2010; Jayasuriya et al., 1989; Rabanal et al., 2002; Schwob et al., 
2002; Vajs et al., 2003).  
 Due to growing interest in antimicrobial agents that can treat infections caused 
by biofilm forming bacteria, the active metabolites (1-5) were tested for their ability to 
attenuate biofilm production by each of the Staphylococcus species. The MBIC values 
of the Hypericum metabolites ranged from 1.95 µg/mL to 7.81 µg/mL. Metabolite 2, 
isolated from H. punctatum, displayed the most potent biofilm inhibition against S. 
aureus and S. epidermidis at an MBIC of 1.95 µg/mL. Compounds 1, 2, and 3 also 
inhibited biofilm formation at concentrations below their respective MIC and MBC 
values against some test strains. Compounds with 2-methylpropanoyl groups (1 and 3) 
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consistently demonstrated MBIC values at or below their respective MIC values. 
Interestingly, a study by Socolsky et al. showed that other acylphloroglucinols isolated 
from Elaphoglossum yungense produced a modest increase in the amount of biofilm of 
S. aureus and P. aeruginosa at 10 µg/mL, despite reducing growth (Socolsky et al., 
2010).  
  The results of these studies add to growing knowledge of the antimicrobial 
properties of acylphloroglucinol metabolites. Other studies have reported 
acylphloroglucinol derivatives possessing antimicrobial activity against staphylococci 
(Gibbons et al., 2005; Henry et al., 2009; Ishiguro et al., 1994; Pecchio et al., 2006; 
Schempp et al., 1999; Winkelmann et al., 2001; Winkelmann et al., 2003). A study by 
Socolsky et al. reported that acylphloroglucinols containing an additional chromene 
substituent possess antimicrobial activity against P. aeruginosa, indicating that certain 
acylphloroglucinols may possess useful antimicrobial effects against Gram-negative 
pathogens (Socolsky et al., 2010). While a detailed mechanism of action for the 
antimicrobial activities of acylphloroglucinols remains to be determined, Hubner and 
colleagues showed that reduced sensitivity of S. aureus to hyperforin did not lead to a 
cross resistance against clinically used antibiotics (Hubner, 2003), therefore 
suggesting a possible unique mechanism of action. Shiu et al. found that certain 
acylphloroglucinols retained activities against tetracyline, fluoroquinolone, and 
macrolide drug-resistant strains, thereby also suggesting alternate mechanisms of 
action (Shiu and Gibbons, 2006). These studies further highlight the promise of 
investigating acylphloroglucinol derivatives as novel agents to treat bacterial disease.   
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Several of the metabolites in this study have previously demonstrated 
biological activities in other medically relevant assays. Compounds 3, 4, 5 and 7 are 
reported to have antitumor activity with IC50 values ranging from 4.1 to 36 µM (Henry 
et al., 2009; Henry et al., 2006). Additionally, compounds 3, 4, and 5 display 
antioxidant activity and cyclooxygenase (COX) inhibition (Henry et al., 2006). 
 The potent anti-staphylococcal activity of the Hypericum metabolites suggests 
that these deserve further consideration as novel antibacterial agents. Staphylococcus 
aureus is recognized as an important human pathogen able to adapt and evolve in 
terms of its resistance traits and virulence factors; it is among the most important 
causes of human infections in both the hospital and community settings (Tang and 
Stratton, 2010). Clinical antibiotics currently used to treat MRSA infections include 
daptomycin, linezolid, and vancomycin.  It is interesting to note that these clinically 
used antibiotics have shown MIC values that are similar to our active Hypericum spp. 
metabolites (Brunton et al., 2006).  These bioactive metabolites further highlight the 
potential for finding structurally new antibacterial agents from plants, and add to our 
understanding of structure-activity relationships for phloroglucinols that limit growth 
and biofilm production by pathogenic bacteria.  
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